Twist Bioscience Corporation announced on October 22, 2024, that it has entered into a royalty purchase agreement with XOMA Royalty Corporation for $15 million in cash. This agreement involves Twist assigning and licensing certain long DNA and other technology, as well as related reagents, to XOMA.
The transaction provides Twist Bioscience with an immediate cash infusion, which can be strategically deployed to support its ongoing operations or to invest in its core synthetic biology and Next-Generation Sequencing (NGS) businesses. This move reflects a financial strategy to leverage future royalty streams for current capital.
The agreement allows Twist to monetize potential future revenues from its biopharma segment, providing financial flexibility. This is a concrete step in managing its asset portfolio and securing non-dilutive funding.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.